Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$125.0K-53.18%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven A. Ledger
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Beta
- 0.03
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -6.74
Financials
Revenue
$125.0K-53.2%Net Income
$-7.91MEBITDA
$-7.68MFree Cash Flow
$-5.50MEPS (diluted)
$-0.31Shares Outstanding (diluted)
25.41M+2394.5%Operating Expenses
$7.99MCash & Debt
$19.40MReturn of Capital
$0.00Revenue by Segment (annual)
$130.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-19.18M | $-1.91 |
| 2024 | $56.0K | $-11.14M | $-1.51 |
| 2023 | $3.15M | $5.27M | $0.63 |
| 2022 | $500.0K | $-2.68M | $-2.49 |
| 2021 | $3.46M | $-1.26M | $-0.59 |
| 2020 | $54.0K | $-10.87M | $-10.14 |
| 2019 | $1.73M | $-12.15M | $-11.47 |
| 2018 | $1.40M | $-7.50M | $-7.56 |
| 2017 | $1.40M | $-6.58M | $-6.46 |
| 2016 | $1.67M | $-15.49M | $-15.21 |
Valuation
SERhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+33.33%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·19d ago·Negative
Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data from the study support the SER-155 mechanisms of strengthening the mucosal epithelial barrier and reducing systemic …
View source ↗ - Newsbusinesswire.com·27d ago·Negative
Custom Truck One Source, Inc. Reports Record Third Quarter 2026 Results and Increases Full Year 2026 Adjusted EBITDA and SER Revenue Guidance KANSAS CITY, Mo.--(BUSINESS WIRE)--Custom Truck One Source, Inc. (NYSE: CTOS), a leading provider of specialty equipment to the electric utility, telecom, rail, forestry, waste management and other infrastructure-related end markets, today reported financial results for the three and nine months ended September 30, 2026. CTOS Third-Quarter Highlights Reven…
View source ↗ - Newsglobenewswire.com·38d ago·Negative
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube
View source ↗ - Newsglobenewswire.com·60d ago·Negative
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress" Featuring Serina Therapeutics' CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson's disease with no major clinical advances in 50+ years Meet with Serina's CEO Steven Ledger Register at AdvancingParkinsonsDisease.TribePublic.com HUNTSVILLE, AL, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Se…
View source ↗ - Newsglobenewswire.com·74d ago·Negative
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2 - Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were consistent with the sustained apomorphine exposure SER-252 is designed to provide – - Blinded Cohort 1 observations included sustained periods of im…
View source ↗ - Newsglobenewswire.com·101d ago·Negative
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the second quarter ended June 30, 2026, along with key business updates.
View source ↗
Earnings
Tue, Mar 30(in 4 months)
Consensus estimate $-0.27 per share
Typical surprise +4.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.31 vs $-0.34beat
- Thu, Aug 13$-0.55 vs $-0.47miss
- Thu, May 14$-0.58 vs $-0.44miss
- Mon, Mar 23$-0.31 vs $-0.50beat
- Thu, Nov 13$-0.45 vs $-0.47beat
- Mon, Aug 11$-0.66 vs $-0.36miss
Estimates and results for SER via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SER officers and directors.
- Bought
- $78k
- Sold
- $386k
7 trades
23 trades
- Brannan Stephen K.bought
- Wilson Karen Jbought
- Wilson Karen Jbought
- Venkatesan Jaybought
- Wilson Karen Jbought
- Wilson Karen Jbought
- Marshall Richard Peterbought
- Moreadith Randallsold
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SER.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
